{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T03:15:10Z","timestamp":1768706110801,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ejca.2018.07.126","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T08:41:00Z","timestamp":1536223260000},"page":"274-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The nephrotoxicity of immune checkpoint inhibitor\u2013based combinations"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7906-0991","authenticated-orcid":false,"given":"Elie","family":"El Rassy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1906-5704","authenticated-orcid":false,"given":"Ziad","family":"Bakouny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fares","family":"Yared","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dania Nehme","family":"Chelala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadi","family":"El Karak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwan","family":"Ghosn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.07.126_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00508-017-1285-9","article-title":"Review of cancer treatment with immune checkpoint inhibitors\u202f: current concepts, expectations, limitations and pitfalls","volume":"130","author":"Thallinger","year":"2018","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.ejca.2018.07.126_bib2","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1080\/14656566.2017.1369956","article-title":"Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies","volume":"18","author":"Flynn","year":"2017","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.ejca.2018.07.126_bib3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2217\/imt-2015-0020","article-title":"A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors","volume":"8","author":"Abdel-Rahman","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ejca.2018.07.126_bib4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000455014","article-title":"Adverse renal effects of immune checkpoint inhibitors: a narrative review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ejca.2018.07.126_bib5","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2018.07.126_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/jjco\/hyv035","article-title":"Onco-nephrology: current concepts and future perspectives","volume":"45","author":"Kitai","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.07.126_bib7","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.07.126_bib8","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1200\/JCO.2016.71.7629","article-title":"Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer","volume":"35","author":"Govindan","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2018.07.126_bib9","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1200\/JCO.2016.66.9861","article-title":"Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Rizvi","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2018.07.126_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.07.126_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.07.126_bib12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.07.126_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study","author":"Hammers","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.07.126_bib14","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.07.126_bib15","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.07.126_bib16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.07.126_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.4504","article-title":"Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: phase 3 study (JAVELIN Renal 101)","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.07.126_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.5010","article-title":"Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)","volume":"32","author":"Amin","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.07.126_bib19","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"0","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.07.126_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.4505","article-title":"IMmotion150: a phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun)","volume":"35","author":"Atkins","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.07.126_bib21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","article-title":"Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial","volume":"18","author":"Gulley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.07.126_bib22","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.07.126_bib23","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.07.126_bib24","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2018.07.126_bib25","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.07.126_bib26","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"0","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.07.126_bib27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejca.2018.07.126_bib28","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ckj\/sfw024","article-title":"Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Murakami","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ejca.2018.07.126_bib29","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejca.2018.07.126_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.6_suppl.578","article-title":"IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC)","volume":"36","author":"Motzer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.07.126_bib31","first-page":"169","article-title":"Onconephrology: what should the internist know about targeted therapy in solid tumors?","volume":"10","author":"El Rassy","year":"2016","journal-title":"Iran J Kidney Dis"},{"key":"10.1016\/j.ejca.2018.07.126_bib32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet Lond Engl"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918311043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918311043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:24:50Z","timestamp":1760732690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918311043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":32,"alternative-id":["S0959804918311043"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.07.126","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The nephrotoxicity of immune checkpoint inhibitor\u2013based combinations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.07.126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}